Startups
Imbria Pharmaceuticals
Develops therapies for cardiometabolic diseases by targeting the heart’s energy metabolism. Its lead candidate, ninerafaxstat, is designed to improve myocardial energy efficiency by shifting energy production from fatty acids toward glucose oxidation, with clinical development focused on non-obstructive hypertrophic cardiomyopathy and heart failure with preserved ejection fraction.
Team
 Albert KimChief Medical Officer |
Alvin ShihChief Executive Officer and Board Member |
Arash YavariChief Scientific Officer |
Charles DunnBoard Member |
Karen JaureguiSVP, Regulatory Affairs, Quality and CMC |
Ken HorneBoard Member |
Komal JoshiChief Financial Officer |
 Laura TadvalkarBoard Member |
Marcus HansenSenior Director, CMC |
Pavan K. CheruvuBoard Chair |
 Rebecca LuseBoard Member |
Sophie KimClinical Trial Manager |
Vanessa MurraySenior Director, Clinical Operations |
Zina Affas BesseBoard Member |